In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

OncoSec Medical Incorporated. Trade Record

NASDAQ:ONCS OncoSec Medical Incorporated stock gains 9.32% Exit Feb 1, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart ONCS Jan 23, 2019, priceSeries
About OncoSec Medical Incorporated

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company's therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
90.76
Entry Date
Jan 23, 2019
Entry Price
7.00
Sell Date
Feb 1, 2019
Sell Price
7.65
Net Gain
9.32%
Hold Time
7 Trading Days